Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma.

Osteosarcomas are copy number alteration (CNA)-rich malignant bone tumors. Using microarrays, fluorescence in situ hybridization, and quantitative PCR, we characterize a focal region of chr3q13.31 (osteo3q13.31) harboring CNAs in 80% of osteosarcomas. As such, osteo3q13.31 is the most altered region in osteosarcoma and contests the view that CNAs in osteosarcoma are nonrecurrent. Most (67%) osteo3q13.31 CNAs are deletions, with 75% of these monoallelic and frequently accompanied by loss of heterozygosity (LOH) in flanking DNA. Notably, these CNAs often involve the noncoding RNAs LOC285194 and BC040587 and, in some cases, a tumor suppressor gene that encodes the limbic system-associated membrane protein (LSAMP). Ubiquitous changes occur in these genes in osteosarcoma, usually involving loss of expression. Underscoring their functional significance, expression of these genes is correlated with the presence of osteo3q13.31 CNAs. Focal osteo3q13.31 CNAs and LOH are also common in cell lines from other cancers, identifying osteo3q13.31 as a generalized candidate region for tumor suppressor genes. Osteo3q13.31 genes may function as a unit, given significant correlation in their expression despite the great genetic distances between them. In support of this notion, depleting either LSAMP or LOC285194 promoted proliferation of normal osteoblasts by regulation of apoptotic and cell-cycle transcripts and also VEGF receptor 1. Moreover, genetic deletions of LOC285194 or BC040587 were also associated with poor survival of osteosarcoma patients. Our findings identify osteo3q13.31 as a novel region of cooperatively acting tumor suppressor genes.

[1]  W. Benedict,et al.  Retinoblastoma: clues to human oncogenesis. , 1984, Science.

[2]  R. Weinberg,et al.  Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Stephen H. Friend,et al.  A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma , 1986, Nature.

[4]  S. Knuutila,et al.  Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. , 1995, Cancer research.

[5]  山口 寿一.  Allelotype analysis in osteosarcomas : frequent allele loss on 3q, 13q, 17p, and 18q , 1996 .

[6]  W. Winkelmann,et al.  Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas , 2002, International journal of cancer.

[7]  S. Friend,et al.  Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma , 1992 .

[8]  C. Larsson,et al.  The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas. , 2003, Cancer cell.

[9]  A. Brøgger,et al.  Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[10]  N. Carter,et al.  A novel mechanistic spectrum underlies glaucoma-associated chromosome 6p25 copy number variation. , 2008, Human molecular genetics.

[11]  E. Zackai,et al.  Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. , 2003, Journal of the National Cancer Institute.

[12]  Chi-Hung Lin,et al.  Identification of chromosomal aberrations associated with disease progression and a novel 3q13.31 deletion involving LSAMP gene in osteosarcoma. , 2009, International journal of oncology.

[13]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[14]  J. Squire,et al.  High‐resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays , 2003, Genes, chromosomes & cancer.

[15]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[16]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[17]  R. Weichselbaum,et al.  Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. , 1992, Cancer research.

[18]  O. Ludkovski,et al.  Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH , 2008, Cytogenetic and Genome Research.

[19]  A. Hüttenhofer,et al.  Methodological obstacles in knocking down small noncoding RNAs. , 2009, RNA.

[20]  Christian J Stoeckert,et al.  STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. , 2006, Genome research.

[21]  O. Myklebost,et al.  Comparative genomic hybridization analysis of human sarcomas: I. Occurrence of genomic imbalances and identification of a novel major amplicon at 1q21–q22 in soft tissue sarcomas , 1995, Genes, chromosomes & cancer.

[22]  J. Squire,et al.  Identification of cryptic microaberrations in osteosarcoma by high-definition oligonucleotide array comparative genomic hybridization. , 2007, Cancer genetics and cytogenetics.

[23]  P. Choong,et al.  Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway , 2008, Molecular Cancer Therapeutics.

[24]  H. Gabra,et al.  The IgLON Family in Epithelial Ovarian Cancer: Expression Profiles and Clinicopathologic Correlates , 2005, Clinical Cancer Research.

[25]  Xiaowu Gai,et al.  High-resolution mapping and analysis of copy number variations in the human genome: a data resource for clinical and research applications. , 2009, Genome research.

[26]  M. Olivier.  A haplotype map of the human genome , 2003, Nature.

[27]  M. Salto‐Tellez,et al.  Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma , 2008, Molecular Biology Reports.

[28]  P. Warnke,et al.  Expression of cellular adhesion molecule ‘OPCML’ is down‐regulated in gliomas and other brain tumours , 2007, Neuropathology and applied neurobiology.

[29]  A. Hall,et al.  A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. , 2009, Blood.

[30]  S. Knuutila,et al.  DNA sequence copy number increase at 8q: A potential new prognostic marker in high‐grade osteosarcoma , 1999, International journal of cancer.

[31]  S A Forbes,et al.  The Catalogue of Somatic Mutations in Cancer (COSMIC) , 2008, Current protocols in human genetics.

[32]  Uri Tabori,et al.  Excessive genomic DNA copy number variation in the Li–Fraumeni cancer predisposition syndrome , 2008, Proceedings of the National Academy of Sciences.

[33]  P. Ambros,et al.  Chromosomal regions involved in the pathogenesis of osteosarcomas. , 1999, Genes, chromosomes & cancer.

[34]  M. Olivier.  A haplotype map of the human genome. , 2003, Nature.

[35]  D. Malkin,et al.  JNK1 determines the oncogenic or tumor-suppressive activity of the integrin-linked kinase in human rhabdomyosarcoma. , 2009, The Journal of clinical investigation.

[36]  Pawel Stankiewicz,et al.  Genomic Disorders: Molecular Mechanisms for Rearrangements and Conveyed Phenotypes , 2005, PLoS genetics.

[37]  P. Sorensen,et al.  Comparative genomic hybridization analysis identifies gains of 1p35 p36 and chromosome 19 in osteosarcoma , 2001 .

[38]  P. Pizzo,et al.  Principles and Practice of Pediatric Oncology , 1989 .

[39]  Stine H. Kresse,et al.  LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization , 2009, Genes, chromosomes & cancer.

[40]  P. Sorensen,et al.  Comparative genomic hybridization analysis identifies gains of 1p35 approximately p36 and chromosome 19 in osteosarcoma. , 2001, Cancer genetics and cytogenetics.

[41]  M. Shibuya,et al.  Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling , 2008, Oncogene.

[42]  David M. Thomas,et al.  Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma , 2004, The Journal of cell biology.